Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center and Professor of Obstetrics and Gynecology at Florida International University, shared a post on LinkedIn about a recent paper he co-authored with colleagues published in the International Journal of Gynecological Cancer:
“This has been a productive year within the Divison of Gynecologic Oncology, Mount Sinai Medical Center.
I’m fortunate to work for an institution that values clinical research and supports our efforts to change the standard of care. Whether in prospective trials or timely reviews.
This article was published today. We review the role of PARP inhibitors in the treatment of endometrial cancer. This class of drugs help our patients with ovarian cancer live longer. Now we are finding they work in endometrial cancer too!
First author is a medical student Griffin Willman who really did a nice job. I’m fortunate to collaborate with some of the brightest researchers in the world.”
Title: Homologous Recombination Deficiency in Endometrial Cancer: Shedding Light on Recent Clinical Findings
Authors: Griffin Willman, Vivek Podder, Shannon Neville Westin, Bradley R. Corr, Robert L. Coleman, Bhavna Pothuri, Kathleen N. Moore, Brian M. Slomovitz
Read the Full Article in the International Journal of Gynecological Cancer.
More posts featuring Brian Slomovitz on OncoDaily.